A Cross-Sectional Study on the Serum Metal Levels in Patients with Type 2 Diabetes Treated with Metformin

A Cross-Sectional Study on the Serum Metal Levels in Patients with Type 2 Diabetes Treated with Metformin - A Study on the Serum Metal Levels in Patients with Type 2 Diabetes Treated with Metformin

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054359

Enrollment

200

Registered

2024-05-10

Start date

2022-07-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diaebtes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Metformin Treatment Group: 1. Diagnosed with type 2 diabetes at the time of registration. 2. Aged 18 years or older. 3. Has been continuously taking metformin for at least six months at the time of registration. 4. Has provided written informed consent for participation in this study. Control Group: Non-Metformin Users: 1. Diagnosed with type 2 diabetes at the time of registration. 2. Aged 18 years or older. 3. Has not been taking metformin continuously for at least six months at the time of registration. 4. Has provided written informed consent for participation in this study.

Exclusion criteria

Exclusion criteria: 1. Patients currently taking iron supplements. 2. Patients currently taking zinc supplements. 3. Patients currently taking vitamin B12 supplements. 4. Patients currently taking folic acid supplements. 5. Patients with anemia. 6. Patients who have undergone gastric, duodenal, or small intestine resection (excluding those who have undergone endoscopic mucosal resection or submucosal dissection). 7. Patients who are pregnant or breastfeeding. 8. Patients with malabsorption issues (e.g., chronic pancreatitis, inflammatory bowel disease, malabsorption syndrome). 9. Patients with renal dysfunction (eGFR < 30 mL/min/1.73m2). 10. Patients with cirrhosis. 11. Patients currently undergoing treatment for malignant tumors. 12. Other patients deemed inappropriate for the study by the investigator.

Design outcomes

Primary

Measure	Time frame
Comparing serum copper levels in patients with type 2 diabetes with and without metformin.	—

Countries

Japan

Contacts

Public ContactNatsu Otowa-Suematsu

Kobe University Graduate School of Medicine Division of Diabetes and Endocrinology

suematsu@med.kobe-u.ac.jp078-382-5861

Outcome results